Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

15.87 -0.45 (-2.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,015,502
Open 15.96
Bid (Size) 15.85 (100)
Ask (Size) 16.25 (1,400)
Prev. Close 16.32
Today's Range 15.75 - 16.30
52wk Range 10.41 - 107.77
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
From Sarepta Therapeutics, Inc.
Via Business Wire

Performance

YTD
-25.5%
-25.5%
1 Month
-23.4%
-23.4%
3 Month
-19.5%
-19.5%
6 Month
-12.6%
-12.6%
1 Year
-84.3%
-84.3%

More News

Read More
News headline image
Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗
Via Chartmill
Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗
Via Stocktwits
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗
Via Stocktwits
News headline image
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗
Via Stocktwits
Topics Earnings
News headline image
Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗
Via Stocktwits
Topics Intellectual Property Lawsuit
News headline image
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
From Sarepta Therapeutics, Inc.
Via Business Wire
Which stocks are moving after the closing bell on Friday? ↗
Via Chartmill
News headline image
Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
2 Beaten-Down Stocks That Could Sink Even More in 2026 ↗
Via The Motley Fool
Topics Death
News headline image
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Why Is SRPT Stock Falling Today? ↗
Via Stocktwits
News headline image
Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027
From Sarepta Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
The current price of Sarepta Therapeutics, Inc. - Common Stock is 15.87
When was Sarepta Therapeutics, Inc. - Common Stock last traded?
The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 03/03/26 04:00 PM ET
What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.48B
How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
Sarepta Therapeutics, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.